Fasoracetam
| |||
| Names | |||
|---|---|---|---|
| IUPAC name
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one | |||
| Other names
(5R)-5-oxo-D-prolinepiperidinamide | |||
| Identifiers | |||
110958-19-5  | |||
| 3D model (Jmol) | Interactive image | ||
| ChEMBL | ChEMBL2106179  | ||
| ChemSpider | 171980 | ||
| KEGG | C13311 | ||
| PubChem | 198695 | ||
| |||
| |||
| Properties | |||
| C10H16N2O2 | |||
| Molar mass | 196.25 g·mol−1 | ||
| Pharmacology | |||
| Oral | |||
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |||
| verify (what is ?) | |||
| Infobox references | |||
Fasoracetam (NS-105, 5-oxo-D-prolinepiperidinamide monohydrate)[1] is a research chemical of the racetam family.[2] It is a nootropic, and has been in a clinical trial for attention deficit hyperactivity disorder.[3]
In in vitro studies on mouse neurons, fasoracetam modulated mGluR II/III activity.[4] In studies in rats, it blocked memory disruptions caused by baclofen, a GABAB agonist[5] and upregulated production of GABAB receptors after repeat dosing.[6]
References
- ↑ FDA/NIH Substance registration system. Page accessed March 21, 2016
- ↑ "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
- ↑ "Drug Profile Fasoracetam".
- ↑ "A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture."..
- ↑ "Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer.".
- ↑ "Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: possible involvement of GABA(B) receptor up-regulation after repeated treatment.".
This article is issued from Wikipedia - version of the 4/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.